Recent Updates
Recently added Catalysts
SMMT Positive Sentiment

Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway

Friday, October 2, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Summit Therapeutics has entered a clinical trial collaboration with Daiichi Sankyo and AstraZeneca to assess ivonescimab, a PD-1/VEGF bispecific antibody. This partnership aims to evaluate the drug in combination with Datroway, a TROP2-directed ADC, across various solid tumors, including breast and lung cancer. The collaboration signifies a strategic move to advance cancer treatment options.

Market Sentiment Analysis

POSITIVE FACTORS

  • Collaboration with major pharmaceutical companies enhances credibility.
  • Potential for innovative treatment options in solid tumors.
  • Focus on multiple cancer types, increasing the scope of research.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+48%
120-day peak, hindsight
Typical move
29.2%
average across 4 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
Ivonescimab
Phase 3 · Metastatic Colorectal Cancer

Full Press Release Details

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced a clinical trial collaboration agreement with Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) to evaluate ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in combination with Datroway® (datopotamab deruxtecan), a TROP2-directed antibody drug conjugate (ADC), across multiple solid tumor settings, intending to include breast and lung cancer. The companies i

Frequently Asked Questions

What is the purpose of the clinical trial collaboration?

The collaboration aims to evaluate ivonescimab in combination with Datroway across multiple solid tumor settings.

Which companies are involved in this collaboration?

The collaboration involves Summit Therapeutics, AstraZeneca, and Daiichi Sankyo.

What types of cancer are being targeted in the trial?

The trial intends to include breast and lung cancer among other solid tumors.

What is ivonescimab?

Ivonescimab is a novel, potential first-in-class PD-1/VEGF bispecific antibody.

ShareAdd on Google
Tags: SMMT Summit Therapeutics AstraZeneca Daiichi Sankyo ivonescimab Datroway
Last updated: Oct 2, 2026

Biotech snapshot

Cash runway
$691M liquidity · $47M/mo burn
~13 mo
Low dilution risk
Lead asset
IvonescimabPhase 3
Metastatic Colorectal Cancer →

Catalyst track record

+48%
best trade around SMMT's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for SMMT.

See every catalyst's timing & PoA →